Title: Licensing Trends in Orphan Drugs Infographic
6,800 rare diseases collectively impacting an estimated 25 million people in the US alone.
Orphan diseases have gotten much attention in recent years:
Since 2009, the FDA granted orphan designations to well over 1000 drugs, a 50% increase from the previous 5 years.
Considerable revenue potential of developing orphan drugs:
• Less competition
• Market exclusivity
• Fast track development
Orphan licensing agreements have seen unique trends in terms of deal values and royalties:
Licenses involving orphan drugs have surpassed other drug deals since 2010
CHART 1 DATA GOES HERE (Average Deal Value) - Attached
Since 2011 the number of deals with a royalty component in the orphan space have increased, especially in 2013.
CHART 2 DATA GOES HERE (Deals with Royalty Component) - Attached
Phase II has proven to be the sweet spot for in-licensing orphan drugs
In the last 5 years, 20% of orphan deals took place at this point, compared to about half that for other deals.
CHART 3 & 4 DATA GOES HERE (Deals with Royalty Component) - Attached
Companies in-licensing orphan drugs:
• Swedish Orphan Biovitrum AB
* SOURCE: The Art of the Deal: Licensing Trends in Orphan Drugs. Download a complimentary copy of the full report at medtrack.com/orphan-drugs-2014